You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZiprasidone
Accession NumberDB00246  (APRD00540)
TypeSmall Molecule
GroupsApproved
DescriptionZiprasidone (marketed as Geodon, Zeldox) was the fifth atypical antipsychotic to gain FDA approval (February 2001). Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania associated with bipolar disorder. [Wikipedia]
Structure
Thumb
Synonyms
Ziprasidona
Ziprasidone
Ziprasidonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-ziprasidonecapsule40 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-ziprasidonecapsule60 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-ziprasidonecapsule80 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-ziprasidonecapsule20 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Geodoncapsule60 mg/1oralRoerig2001-02-05Not applicableUs
Geodoncapsule20 mg/1oralRoerig2013-11-01Not applicableUs
Geodoncapsule80 mg/1oralREMEDYREPACK INC.2010-12-20Not applicableUs
Geodoncapsule80 mg/1oralCardinal Health2001-02-05Not applicableUs
Geodoncapsule40 mg/1oralRebel Distributors Corp2001-02-05Not applicableUs
Geodoncapsule40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Geodoninjection, powder, lyophilized, for solution20 mg/mLintramuscularRoerig2003-12-23Not applicableUs
Geodoncapsule20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-11-05Not applicableUs
Geodoncapsule80 mg/1oralRoerig2001-02-05Not applicableUs
Geodoninjection, powder, lyophilized, for solution20 mg/mLintramuscularREMEDYREPACK INC.2015-02-13Not applicableUs
Geodoncapsule40 mg/1oralRoerig2013-11-01Not applicableUs
Geodoncapsule20 mg/1oralREMEDYREPACK INC.2010-12-20Not applicableUs
Geodoninjection, powder, lyophilized, for solution20 mg/mLintramuscularCardinal Health2003-12-23Not applicableUs
Geodoncapsule60 mg/1oralRebel Distributors Corp2001-02-05Not applicableUs
Geodoncapsule60 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Geodoncapsule60 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-27Not applicableUs
Geodoncapsule20 mg/1oralRoerig2001-02-05Not applicableUs
Geodoncapsule20 mg/1oralSTAT Rx USA LLC2001-02-05Not applicableUs
Geodoninjection, powder, lyophilized, for solution20 mg/mLintramuscularTYA Pharmaceuticals2003-12-23Not applicableUs
Geodoncapsule60 mg/1oralRoerig2013-11-01Not applicableUs
Geodoncapsule60 mg/1oralREMEDYREPACK INC.2010-12-20Not applicableUs
Geodoncapsule40 mg/1oralCardinal Health2001-02-05Not applicableUs
Geodoncapsule80 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Geodoncapsule80 mg/1oralRebel Distributors Corp2001-02-05Not applicableUs
Geodoncapsule20 mg/1oralUnit Dose Services2001-02-05Not applicableUs
Geodoncapsule40 mg/1oralRoerig2001-02-05Not applicableUs
Geodoncapsule20 mg/1oralRebel Distributors Corp2001-02-05Not applicableUs
Geodoncapsule20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Geodoncapsule80 mg/1oralRoerig2013-11-01Not applicableUs
Geodoncapsule80 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2001-02-05Not applicableUs
Geodoncapsule60 mg/1oralCardinal Health2001-02-05Not applicableUs
Geodoncapsule20 mg/1oralCardinal Health2001-02-05Not applicableUs
Geodoncapsule40 mg/1oralREMEDYREPACK INC.2010-12-20Not applicableUs
Zeldoxcapsule40 mgoralPfizer Canada Inc2008-01-04Not applicableCanada
Zeldoxcapsule60 mgoralPfizer Canada Inc2008-01-04Not applicableCanada
Zeldoxcapsule80 mgoralPfizer Canada Inc2008-01-04Not applicableCanada
Zeldoxcapsule20.0 mgoralPfizer Canada Inc2008-01-04Not applicableCanada
Ziprasidonecapsule20 mg/1oralREMEDYREPACK INC.2013-01-04Not applicableUs
Ziprasidonecapsule80 mg/1oralGreenstone LLC2001-02-05Not applicableUs
Ziprasidonecapsule20 mg/1oralGreenstone LLC2001-02-05Not applicableUs
Ziprasidonecapsule60 mg/1oralREMEDYREPACK INC.2013-03-27Not applicableUs
Ziprasidonecapsule40 mg/1oralGreenstone LLC2001-02-05Not applicableUs
Ziprasidonecapsule40 mg/1oralREMEDYREPACK INC.2013-05-02Not applicableUs
Ziprasidonecapsule60 mg/1oralGreenstone LLC2001-02-05Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ziprasidone Hydrochloridecapsule80 mg/1oralApotex Corp.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralTYA Pharmaceuticals2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralSandoz Inc2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralRebel Distributors Corp2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralREMEDYREPACK INC.2016-02-25Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralProficient Rx LP2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralREMEDYREPACK INC.2014-04-25Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralCardinal Health2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralTYA Pharmaceuticals2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralApotex Corp.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralREMEDYREPACK INC.2013-02-15Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralSandoz Inc2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralREMEDYREPACK INC.2014-10-21Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralTYA Pharmaceuticals2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralRebel Distributors Corp2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralREMEDYREPACK INC.2016-03-01Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralREMEDYREPACK INC.2014-06-24Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralProficient Rx LP2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralApotex Corp.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralUnit Dose Services2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralCardinal Health2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralTYA Pharmaceuticals2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralSandoz Inc2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralREMEDYREPACK INC.2014-10-30Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralREMEDYREPACK INC.2013-02-08Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralCardinal Health2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralREMEDYREPACK INC.2013-02-08Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralProficient Rx LP2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralREMEDYREPACK INC.2016-02-10Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralRebel Distributors Corp2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralApotex Corp.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralCardinal Health2013-07-02Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralTYA Pharmaceuticals2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralSandoz Inc2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralREMEDYREPACK INC.2014-11-12Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralREMEDYREPACK INC.2014-03-03Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralREMEDYREPACK INC.2013-02-08Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralCardinal Health2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralProficient Rx LP2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralREMEDYREPACK INC.2016-02-10Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralRebel Distributors Corp2012-03-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ziprasidone hydrochloride
Thumb
  • InChI Key: ZCBZSCBNOOIHFP-UHFFFAOYSA-N
  • Monoisotopic Mass: 466.099702136
  • Average Mass: 467.412
DBSALT000810
Ziprasidone mesylate trihydrate
Thumb
  • InChI Key: WLQZEFFFIUHSJB-UHFFFAOYSA-N
  • Monoisotopic Mass: 562.132268453
  • Average Mass: 563.087
DBSALT000811
Categories
UNII6UKA5VEJ6X
CAS number146939-27-7
WeightAverage: 412.936
Monoisotopic: 412.112459711
Chemical FormulaC21H21ClN4OS
InChI KeyMVWVFYHBGMAFLY-UHFFFAOYSA-N
InChI
InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
IUPAC Name
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one
SMILES
ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenethylamine
  • Dihydroindole
  • Indole or derivatives
  • 1,2-benzothiazole
  • Dialkylarylamine
  • Aralkylamine
  • N-alkylpiperazine
  • Chlorobenzene
  • Imidolactam
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Thiazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of schizophrenia and related psychotic disorders.
PharmacodynamicsZiprasidone is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Ziprasidone is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Ziprasidone acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Ziprasidone. Ziprasidone's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Ziprasidone's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Ziprasidone's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug. Ziprasidone functions as an antagonist at the Dopamine D2 , 5HT-2A , and 5HT-1D receptors, and as an agonist at the 5HT-1A receptor. Ziprasidone also inhibits synaptic reuptake of serotonin and norepinephrine.
Mechanism of actionZiprasidone's antipsychotic activity is likely due to a combination of its antagonistic function at D2 receptors in the mesolimbic pathways and at 5HT2A receptors in the frontal cortex. Alleviation of positive symptoms is due to antagonism at D2 receptors while relief of negative symptoms are due to 5HT2A antagonism.
Related Articles
Absorption~60%
Volume of distribution
  • 1.5 L/kg
Protein binding99%
Metabolism

Hepatic

SubstrateEnzymesProduct
Ziprasidone
benzisothiazole piperazineDetails
Route of eliminationZiprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug. Approximately 20% of the dose is excreted in the urine, with approximately 66% being eliminated in the feces.
Half life7 hours
Clearance
  • 7.5 mL/min/kg
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9759
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7167
P-glycoprotein inhibitor IInhibitor0.8052
P-glycoprotein inhibitor IIInhibitor0.6419
Renal organic cation transporterInhibitor0.5325
CYP450 2C9 substrateNon-substrate0.7972
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.6576
CYP450 2C9 inhibitorInhibitor0.6329
CYP450 2D6 inhibitorNon-inhibitor0.7151
CYP450 2C19 inhibitorInhibitor0.8086
CYP450 3A4 inhibitorNon-inhibitor0.7723
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9567
Ames testNon AMES toxic0.6273
CarcinogenicityNon-carcinogens0.8672
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5877 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6826
hERG inhibition (predictor II)Inhibitor0.7753
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
Packagers
Dosage forms
FormRouteStrength
Capsuleoral20 mg
Capsuleoral20 mg/1
Capsuleoral40 mg/1
Capsuleoral60 mg/1
Capsuleoral80 mg/1
Injection, powder, lyophilized, for solutionintramuscular20 mg/mL
Capsuleoral20.0 mg
Capsuleoral40 mg
Capsuleoral60 mg
Capsuleoral80 mg
Prices
Unit descriptionCostUnit
Zoladex 10.8 mg Implant Syringe1407.72USD syringe
Geodon 20 mg vial16.22USD vial
Geodon 60 mg capsule9.88USD capsule
Geodon 80 mg capsule9.88USD capsule
Geodon 20 mg capsule8.14USD capsule
Geodon 40 mg capsule8.14USD capsule
Zeldox 40 mg Capsule2.13USD capsule
Zeldox 60 mg Capsule2.13USD capsule
Zeldox 80 mg Capsule2.13USD capsule
Zeldox 20 mg Capsule1.86USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2105114 No2000-02-152013-08-30Canada
CA2256227 No2003-07-012018-12-16Canada
US5134127 No1993-01-232010-01-23Us
US6110918 No1997-03-262017-03-26Us
US6150366 No1999-05-272019-05-27Us
US6232304 No1997-04-012017-04-01Us
US6245766 No1998-12-182018-12-18Us
US6399777 No1997-04-012017-04-01Us
US7175855 No2000-05-182020-05-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point>300 °CNot Available
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00718 mg/mLALOGPS
logP4.64ALOGPS
logP4.3ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.18ChemAxon
pKa (Strongest Basic)7.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area48.47 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity116.72 m3·mol-1ChemAxon
Polarizability44.96 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Frank R. Busch, Carol A. Rose, “Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist.” U.S. Patent US6110918, issued January, 1995.

US6110918
General References
  1. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  2. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001 Aug 17;425(3):197-201. [PubMed:11513838 ]
External Links
ATC CodesN05AE04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (75 KB)
MSDSDownload (57.8 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineZiprasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineZiprasidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ziprasidone.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ziprasidone is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Ziprasidone can be increased when it is combined with Abiraterone.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Ziprasidone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Ziprasidone.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Ziprasidone.
AcepromazineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Ziprasidone.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ziprasidone.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Ziprasidone.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Ziprasidone.
adipiplonThe risk or severity of adverse effects can be increased when Ziprasidone is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Agomelatine.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Ziprasidone.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Ziprasidone.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Ziprasidone.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Ziprasidone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Alfaxalone.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Ziprasidone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ziprasidone.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Ziprasidone.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Ziprasidone.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Ziprasidone.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Ziprasidone.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ziprasidone.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Ziprasidone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ziprasidone.
AlosetronThe metabolism of Alosetron can be decreased when combined with Ziprasidone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Alphacetylmethadol.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Ziprasidone.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ziprasidone.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Ziprasidone.
AmantadineAmantadine may increase the QTc-prolonging activities of Ziprasidone.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Ziprasidone.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Ziprasidone.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Ziprasidone.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Ziprasidone.
AmiodaroneZiprasidone may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ziprasidone.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Ziprasidone.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Ziprasidone.
AmobarbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amperozide.
AmphetamineZiprasidone may decrease the stimulatory activities of Amphetamine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Ziprasidone.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Ziprasidone.
AnagrelideZiprasidone may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Ziprasidone.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ziprasidone.
ApomorphineApomorphine may increase the QTc-prolonging activities of Ziprasidone.
ApremilastThe metabolism of Apremilast can be decreased when combined with Ziprasidone.
AprepitantThe serum concentration of Ziprasidone can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Ziprasidone.
AprindineThe metabolism of Aprindine can be decreased when combined with Ziprasidone.
ArformoterolArformoterol may increase the QTc-prolonging activities of Ziprasidone.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Ziprasidone.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Ziprasidone.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ziprasidone.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ziprasidone.
Arsenic trioxideZiprasidone may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherZiprasidone may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Articaine.
AsenapineZiprasidone may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Ziprasidone.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Ziprasidone.
AtomoxetineThe metabolism of Ziprasidone can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Ziprasidone.
AvanafilThe metabolism of Avanafil can be decreased when combined with Ziprasidone.
AxitinibThe metabolism of Axitinib can be decreased when combined with Ziprasidone.
AzaperoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Azaperone.
AzelastineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ziprasidone.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Ziprasidone.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Ziprasidone.
BaclofenThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Baclofen.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Ziprasidone.
BarbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Barbital.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Ziprasidone.
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Ziprasidone.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Ziprasidone.
BenzocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Benzocaine.
BenzphetamineZiprasidone may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Ziprasidone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ziprasidone.
BepridilThe metabolism of Bepridil can be decreased when combined with Ziprasidone.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Ziprasidone.
BexaroteneThe serum concentration of Ziprasidone can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Ziprasidone.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Ziprasidone.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Ziprasidone.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Ziprasidone.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Ziprasidone.
BortezomibThe metabolism of Ziprasidone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ziprasidone can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Ziprasidone.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ziprasidone.
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Ziprasidone.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Ziprasidone.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Ziprasidone.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
BrimonidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Brimonidine.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Ziprasidone.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Ziprasidone.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ziprasidone.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ziprasidone.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Ziprasidone.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Ziprasidone.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ziprasidone.
BrotizolamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Brotizolam.
BudesonideThe metabolism of Budesonide can be decreased when combined with Ziprasidone.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Ziprasidone.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Ziprasidone.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Ziprasidone.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ziprasidone.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Ziprasidone.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ziprasidone.
BupropionThe metabolism of Bupropion can be decreased when combined with Ziprasidone.
BuserelinBuserelin may increase the QTc-prolonging activities of Ziprasidone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ziprasidone.
BuspironeThe metabolism of Buspirone can be decreased when combined with Ziprasidone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Ziprasidone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ziprasidone.
ButacaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butorphanol.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Ziprasidone.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ziprasidone.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Ziprasidone.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Ziprasidone.
CaffeineThe metabolism of Caffeine can be decreased when combined with Ziprasidone.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Ziprasidone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.
CaptoprilThe metabolism of Captopril can be decreased when combined with Ziprasidone.
CarbamazepineThe serum concentration of Ziprasidone can be decreased when it is combined with Carbamazepine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Ziprasidone.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Ziprasidone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ziprasidone.
CarfentanilThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Carfentanil.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Ziprasidone.
CarisoprodolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Carisoprodol.
CarteololThe metabolism of Carteolol can be decreased when combined with Ziprasidone.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Ziprasidone.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ziprasidone.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Ziprasidone.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Ziprasidone.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Ziprasidone.
CeritinibCeritinib may increase the QTc-prolonging activities of Ziprasidone.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Ziprasidone.
CetirizineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Ziprasidone.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Ziprasidone.
Chloral hydrateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloral hydrate.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Ziprasidone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ziprasidone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloroprocaine.
ChloroquineChloroquine may increase the QTc-prolonging activities of Ziprasidone.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Ziprasidone.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Ziprasidone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ziprasidone.
ChlorphentermineZiprasidone may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Ziprasidone.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Ziprasidone.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ziprasidone.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Ziprasidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ziprasidone.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Ziprasidone.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Ziprasidone.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ziprasidone.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Ziprasidone.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Ziprasidone.
CinchocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cinchocaine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Ziprasidone.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Ziprasidone.
CisaprideZiprasidone may increase the QTc-prolonging activities of Cisapride.
CitalopramCitalopram may increase the QTc-prolonging activities of Ziprasidone.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Ziprasidone.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Ziprasidone.
ClemastineThe metabolism of Ziprasidone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Ziprasidone.
ClidiniumThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Clidinium.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Ziprasidone.
ClobazamThe metabolism of Clobazam can be decreased when combined with Ziprasidone.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ziprasidone.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Ziprasidone.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Ziprasidone.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Ziprasidone.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Ziprasidone.
ClomipramineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Clomipramine.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Ziprasidone.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Ziprasidone.
ClonidineThe metabolism of Clonidine can be decreased when combined with Ziprasidone.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ziprasidone.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Ziprasidone.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Ziprasidone.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ziprasidone.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Ziprasidone.
ClotrimazoleThe metabolism of Ziprasidone can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Ziprasidone.
ClozapineThe metabolism of Clozapine can be decreased when combined with Ziprasidone.
CobicistatThe metabolism of Ziprasidone can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ziprasidone.
CocaineThe metabolism of Cocaine can be decreased when combined with Ziprasidone.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ziprasidone.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Ziprasidone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ziprasidone.
ColchicineThe metabolism of Colchicine can be decreased when combined with Ziprasidone.
ConivaptanThe serum concentration of Ziprasidone can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Ziprasidone.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Ziprasidone.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Ziprasidone.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Ziprasidone.
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Ziprasidone.
CyclizineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ziprasidone.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Ziprasidone.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Ziprasidone.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Ziprasidone.
CyproheptadineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Ziprasidone can be decreased when it is combined with Cyproterone acetate.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Ziprasidone.
DabrafenibThe serum concentration of Ziprasidone can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Ziprasidone.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Ziprasidone.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Ziprasidone.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ziprasidone.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Ziprasidone.
DapiprazoleThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dapoxetine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Ziprasidone.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Ziprasidone.
DarunavirThe metabolism of Darunavir can be decreased when combined with Ziprasidone.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Ziprasidone.
DasatinibThe serum concentration of Ziprasidone can be increased when it is combined with Dasatinib.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Ziprasidone.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Ziprasidone.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Ziprasidone.
DeferasiroxThe serum concentration of Ziprasidone can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Ziprasidone.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Ziprasidone.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Ziprasidone.
deramciclaneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ziprasidone.
DesipramineThe metabolism of Desipramine can be decreased when combined with Ziprasidone.
DesloratadineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ziprasidone.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Ziprasidone.
DetomidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Detomidine.
DexamethasoneThe serum concentration of Ziprasidone can be decreased when it is combined with Dexamethasone.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Ziprasidone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexbrompheniramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Ziprasidone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexmedetomidine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Ziprasidone.
DextroamphetamineZiprasidone may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ziprasidone.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Ziprasidone.
DextromoramideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dextromoramide.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Ziprasidone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ziprasidone.
DezocineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dezocine.
DiazepamThe metabolism of Diazepam can be decreased when combined with Ziprasidone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ziprasidone.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Ziprasidone.
DifenoxinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Difenoxin.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Ziprasidone.
DigoxinThe metabolism of Digoxin can be decreased when combined with Ziprasidone.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Ziprasidone.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ziprasidone.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ziprasidone.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Ziprasidone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydromorphine.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Ziprasidone.
DimenhydrinateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Ziprasidone.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ziprasidone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Diphenoxylate.
DisopyramideZiprasidone may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Ziprasidone.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Ziprasidone.
DofetilideDofetilide may increase the QTc-prolonging activities of Ziprasidone.
DolasetronDolasetron may increase the QTc-prolonging activities of Ziprasidone.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Ziprasidone.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ziprasidone.
DomperidoneDomperidone may increase the QTc-prolonging activities of Ziprasidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Ziprasidone.
DopamineThe metabolism of Dopamine can be decreased when combined with Ziprasidone.
DoramectinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Doramectin.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Ziprasidone.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Ziprasidone.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Ziprasidone.
DoxepinThe metabolism of Doxepin can be decreased when combined with Ziprasidone.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Ziprasidone.
DoxycyclineThe metabolism of Ziprasidone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
DoxylamineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Ziprasidone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Ziprasidone.
DronedaroneZiprasidone may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Ziprasidone.
DroperidolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Drotebanol.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ziprasidone.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ziprasidone.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Ziprasidone.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Ziprasidone.
DyclonineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ziprasidone is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Ziprasidone can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Ziprasidone.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ziprasidone.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Ziprasidone.
EliglustatZiprasidone may increase the QTc-prolonging activities of Eliglustat.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Ziprasidone.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Ziprasidone.
EncainideThe metabolism of Encainide can be decreased when combined with Ziprasidone.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Ziprasidone.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ziprasidone.
EntacaponeThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Entacapone.
EnzalutamideThe serum concentration of Ziprasidone can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Ziprasidone.
EpinastineThe metabolism of Epinastine can be decreased when combined with Ziprasidone.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Ziprasidone.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Ziprasidone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ziprasidone.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Ziprasidone.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ziprasidone.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Ziprasidone.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ziprasidone.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Ziprasidone.
EribulinEribulin may increase the QTc-prolonging activities of Ziprasidone.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Ziprasidone.
ErythromycinErythromycin may increase the QTc-prolonging activities of Ziprasidone.
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Ziprasidone.
EscitalopramZiprasidone may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Ziprasidone can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Ziprasidone.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Ziprasidone.
EstazolamThe metabolism of Estazolam can be decreased when combined with Ziprasidone.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ziprasidone.
EstradiolThe metabolism of Estradiol can be decreased when combined with Ziprasidone.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Ziprasidone.
EstramustineThe metabolism of Estramustine can be decreased when combined with Ziprasidone.
EstroneThe metabolism of Estrone can be decreased when combined with Ziprasidone.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Ziprasidone.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Ziprasidone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ziprasidone.
EthanolZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Ziprasidone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziprasidone.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Ziprasidone.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Ziprasidone.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ziprasidone.
EthotoinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl loflazepate.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Ziprasidone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ziprasidone.
EtidocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etomidate.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Ziprasidone.
EtoperidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etoperidone.
EtoposideThe metabolism of Etoposide can be decreased when combined with Ziprasidone.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Ziprasidone.
EtorphineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etorphine.
EtravirineThe serum concentration of Ziprasidone can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Ziprasidone.
EverolimusThe metabolism of Everolimus can be decreased when combined with Ziprasidone.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Ziprasidone.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Ziprasidone.
EzogabineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ezogabine.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Ziprasidone.
FamotidineFamotidine may increase the QTc-prolonging activities of Ziprasidone.
FelbamateThe metabolism of Felbamate can be decreased when combined with Ziprasidone.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Ziprasidone.
FelodipineThe metabolism of Felodipine can be decreased when combined with Ziprasidone.
FencamfamineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fenfluramine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Ziprasidone.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ziprasidone.
FentanylThe metabolism of Fentanyl can be decreased when combined with Ziprasidone.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ziprasidone.
FexofenadineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fexofenadine.
FinasterideThe metabolism of Finasteride can be decreased when combined with Ziprasidone.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Ziprasidone.
FingolimodFingolimod may increase the QTc-prolonging activities of Ziprasidone.
FlecainideFlecainide may increase the QTc-prolonging activities of Ziprasidone.
FlecainideThe metabolism of Flecainide can be decreased when combined with Ziprasidone.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ziprasidone.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ziprasidone.
FluconazoleThe metabolism of Ziprasidone can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Ziprasidone.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ziprasidone.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Ziprasidone.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Ziprasidone.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ziprasidone.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Ziprasidone.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Ziprasidone.
FlupentixolZiprasidone may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Ziprasidone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ziprasidone.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Ziprasidone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ziprasidone.
FluspirileneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluspirilene.
FlutamideThe metabolism of Flutamide can be decreased when combined with Ziprasidone.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Ziprasidone.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Ziprasidone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ziprasidone.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Ziprasidone.
FluvoxamineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Ziprasidone.
FormoterolThe metabolism of Formoterol can be decreased when combined with Ziprasidone.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Ziprasidone.
FosaprepitantThe serum concentration of Ziprasidone can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Ziprasidone.
FosphenytoinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Ziprasidone.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Ziprasidone.
Fusidic AcidThe serum concentration of Ziprasidone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ziprasidone is combined with gabapentin enacarbil.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Ziprasidone.
GalantamineThe metabolism of Galantamine can be decreased when combined with Ziprasidone.
GalantamineGalantamine may increase the QTc-prolonging activities of Ziprasidone.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Gamma Hydroxybutyric Acid.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Ziprasidone.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Ziprasidone.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Ziprasidone.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ziprasidone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Ziprasidone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ziprasidone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Ziprasidone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ziprasidone.
GlutethimideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Glutethimide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Ziprasidone.
GoserelinGoserelin may increase the QTc-prolonging activities of Ziprasidone.
GranisetronGranisetron may increase the QTc-prolonging activities of Ziprasidone.
GranisetronThe metabolism of Granisetron can be decreased when combined with Ziprasidone.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Ziprasidone.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Ziprasidone.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ziprasidone.
HalazepamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Halazepam.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Ziprasidone.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Ziprasidone.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Ziprasidone.
HalothaneThe metabolism of Halothane can be decreased when combined with Ziprasidone.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ziprasidone.
HeroinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Heroin.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Ziprasidone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ziprasidone.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Ziprasidone.
HistrelinHistrelin may increase the QTc-prolonging activities of Ziprasidone.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Ziprasidone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ziprasidone.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Ziprasidone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Ziprasidone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ziprasidone.
Hydroxyamphetamine hydrobromideZiprasidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Ziprasidone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
HydroxyzineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Ziprasidone.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Ziprasidone.
IbutilideZiprasidone may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Ziprasidone.
IdelalisibThe serum concentration of Ziprasidone can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Ziprasidone resulting in a loss in efficacy.
IloperidoneZiprasidone may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ziprasidone.
ImatinibThe metabolism of Ziprasidone can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ziprasidone.
ImipramineThe metabolism of Imipramine can be decreased when combined with Ziprasidone.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Ziprasidone.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Ziprasidone.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Ziprasidone.
IndalpineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Indalpine.
IndapamideThe metabolism of Indapamide can be decreased when combined with Ziprasidone.
IndapamideIndapamide may increase the QTc-prolonging activities of Ziprasidone.
IndinavirThe metabolism of Indinavir can be decreased when combined with Ziprasidone.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ziprasidone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ziprasidone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ziprasidone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ziprasidone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ziprasidone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ziprasidone.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Ziprasidone.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Ziprasidone.
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Ziprasidone.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ziprasidone.
IsofluraneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Isoflurane.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ziprasidone.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ziprasidone.
IsradipineThe metabolism of Isradipine can be decreased when combined with Ziprasidone.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Ziprasidone.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Ziprasidone.
IvabradineIvabradine may increase the QTc-prolonging activities of Ziprasidone.
IvacaftorThe serum concentration of Ziprasidone can be increased when it is combined with Ivacaftor.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Ziprasidone.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Ziprasidone.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Ziprasidone.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Ziprasidone.
KetamineThe metabolism of Ketamine can be decreased when combined with Ziprasidone.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ziprasidone.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Ziprasidone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ziprasidone.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Ziprasidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ziprasidone.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Ziprasidone.
LabetalolThe metabolism of Labetalol can be decreased when combined with Ziprasidone.
LamotrigineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Lamotrigine.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Ziprasidone.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Ziprasidone.
LapatinibLapatinib may increase the QTc-prolonging activities of Ziprasidone.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Ziprasidone.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Ziprasidone.
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Ziprasidone.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Ziprasidone.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Ziprasidone.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Ziprasidone.
LevetiracetamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levetiracetam.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Ziprasidone.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ziprasidone.
LevocabastineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levocabastine.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Ziprasidone.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ziprasidone.
LevodopaThe metabolism of Levodopa can be decreased when combined with Ziprasidone.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Ziprasidone.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Ziprasidone.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Ziprasidone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ziprasidone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levomilnacipran.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Ziprasidone.
LevorphanolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levorphanol.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Ziprasidone.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Ziprasidone.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Ziprasidone.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ziprasidone.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Ziprasidone.
LisdexamfetamineZiprasidone may decrease the stimulatory activities of Lisdexamfetamine.
LisurideThe metabolism of Lisuride can be decreased when combined with Ziprasidone.
LithiumLithium may increase the neurotoxic activities of Ziprasidone.
LithiumThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Lofentanil.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Ziprasidone.
LomustineThe metabolism of Lomustine can be decreased when combined with Ziprasidone.
LoperamideThe metabolism of Loperamide can be decreased when combined with Ziprasidone.
LopinavirZiprasidone may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Ziprasidone.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ziprasidone.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ziprasidone.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ziprasidone.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Ziprasidone.
LosartanThe metabolism of Losartan can be decreased when combined with Ziprasidone.
LovastatinThe metabolism of Ziprasidone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Ziprasidone is combined with Lu AA21004.
LuliconazoleThe serum concentration of Ziprasidone can be increased when it is combined with Luliconazole.
LumefantrineZiprasidone may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Ziprasidone.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ziprasidone.
MacitentanThe metabolism of Macitentan can be decreased when combined with Ziprasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ziprasidone.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Ziprasidone.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Ziprasidone.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Ziprasidone.
MeclizineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Medetomidine.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Ziprasidone.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Ziprasidone.
MefloquineMefloquine may increase the QTc-prolonging activities of Ziprasidone.
MelatoninThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Melatonin.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Ziprasidone.
MelperoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Melperone.
MephentermineZiprasidone may decrease the stimulatory activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Ziprasidone.
MepivacaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Meprobamate.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Ziprasidone.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Ziprasidone.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ziprasidone.
MetaxaloneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Metaxalone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone.
MethadoneMethadone may increase the QTc-prolonging activities of Ziprasidone.
MethadoneThe metabolism of Methadone can be decreased when combined with Ziprasidone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methadyl Acetate.
MethamphetamineZiprasidone may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methapyrilene.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Ziprasidone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ziprasidone.
MethocarbamolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methohexital.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Ziprasidone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ziprasidone.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Ziprasidone.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Ziprasidone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ziprasidone.
MethsuximideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenobarbital.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Ziprasidone.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Ziprasidone.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Ziprasidone.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Ziprasidone.
MetoprololThe metabolism of Metoprolol can be decreased when combined with Ziprasidone.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Ziprasidone.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Ziprasidone.
MetyrosineZiprasidone may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Ziprasidone.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Ziprasidone.
MianserinThe metabolism of Mianserin can be decreased when combined with Ziprasidone.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Ziprasidone.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Ziprasidone.
MidazolamThe metabolism of Midazolam can be decreased when combined with Ziprasidone.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ziprasidone.
MifepristoneMifepristone may increase the QTc-prolonging activities of Ziprasidone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ziprasidone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Ziprasidone.
MilnacipranThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Milnacipran.
MinaprineThe metabolism of Minaprine can be decreased when combined with Ziprasidone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Ziprasidone.
MirabegronMirabegron may increase the QTc-prolonging activities of Ziprasidone.
MirtazapineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ziprasidone.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ziprasidone.
MitotaneThe serum concentration of Ziprasidone can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ziprasidone.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Ziprasidone.
ModafinilThe serum concentration of Ziprasidone can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Ziprasidone.
MoexiprilMoexipril may increase the QTc-prolonging activities of Ziprasidone.
MolindoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Molindone.
MontelukastThe metabolism of Montelukast can be decreased when combined with Ziprasidone.
MorphineThe metabolism of Morphine can be decreased when combined with Ziprasidone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ziprasidone.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Ziprasidone.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Ziprasidone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
NabiloneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Nabilone.
NafcillinThe serum concentration of Ziprasidone can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ziprasidone.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Ziprasidone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ziprasidone.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Ziprasidone.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Ziprasidone.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Ziprasidone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Ziprasidone.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Ziprasidone.
NetupitantThe serum concentration of Ziprasidone can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Ziprasidone.
NevirapineThe metabolism of Ziprasidone can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Ziprasidone.
NicardipineNicardipine may increase the QTc-prolonging activities of Ziprasidone.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Ziprasidone.
NicotineThe metabolism of Nicotine can be decreased when combined with Ziprasidone.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Ziprasidone.
NilotinibZiprasidone may increase the QTc-prolonging activities of Nilotinib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Ziprasidone.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Ziprasidone.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ziprasidone.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Ziprasidone.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Ziprasidone.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ziprasidone.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Ziprasidone.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Ziprasidone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Nitrous oxide.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Ziprasidone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Ziprasidone.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Ziprasidone.
NormethadoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ziprasidone.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Ziprasidone.
OctreotideOctreotide may increase the QTc-prolonging activities of Ziprasidone.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Ziprasidone.
OlanzapineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Ziprasidone.
OlaparibThe metabolism of Ziprasidone can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Ziprasidone.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Ziprasidone.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ziprasidone.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Ziprasidone.
OndansetronOndansetron may increase the QTc-prolonging activities of Ziprasidone.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Ziprasidone.
OpiumThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Opium.
OrphenadrineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ziprasidone.
OsanetantThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Osanetant.
OsimertinibThe serum concentration of Ziprasidone can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Ziprasidone.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Ziprasidone.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ziprasidone.
OxprenololThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxybuprocaine.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Ziprasidone.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Ziprasidone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ziprasidone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Ziprasidone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ziprasidone.
OxytocinOxytocin may increase the QTc-prolonging activities of Ziprasidone.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Ziprasidone.
PalbociclibThe serum concentration of Ziprasidone can be increased when it is combined with Palbociclib.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Ziprasidone.
PaliperidoneZiprasidone may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Ziprasidone.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Ziprasidone.
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Ziprasidone.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Ziprasidone.
ParaldehydeZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Ziprasidone.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Ziprasidone.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Ziprasidone.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Ziprasidone.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Ziprasidone.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Ziprasidone.
ParoxetineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Ziprasidone.
PazopanibPazopanib may increase the QTc-prolonging activities of Ziprasidone.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Ziprasidone.
Peginterferon alfa-2bThe serum concentration of Ziprasidone can be increased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Ziprasidone.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Ziprasidone.
PentazocineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Ziprasidone.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Ziprasidone.
PerflutrenPerflutren may increase the QTc-prolonging activities of Ziprasidone.
PergolideThe metabolism of Pergolide can be decreased when combined with Ziprasidone.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Ziprasidone.
PermethrinThe metabolism of Permethrin can be decreased when combined with Ziprasidone.
PerospironeThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Perospirone.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Ziprasidone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ziprasidone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ziprasidone.
PethidineThe metabolism of Pethidine can be decreased when combined with Ziprasidone.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Ziprasidone.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ziprasidone.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Ziprasidone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Phenobarbital.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Ziprasidone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Phenoxyethanol.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Ziprasidone.
PhentermineZiprasidone may decrease the stimulatory activities of Phentermine.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Ziprasidone.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ziprasidone.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Ziprasidone.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Ziprasidone.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ziprasidone.
PimozidePimozide may increase the QTc-prolonging activities of Ziprasidone.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Ziprasidone.
PindololThe metabolism of Pindolol can be decreased when combined with Ziprasidone.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ziprasidone.
PipamperoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Ziprasidone.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Ziprasidone.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ziprasidone.
PizotifenThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pizotifen.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Ziprasidone.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Ziprasidone.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ziprasidone.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Ziprasidone.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Ziprasidone.
PramipexoleZiprasidone may increase the sedative activities of Pramipexole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Ziprasidone.
PramocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pramocaine.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Ziprasidone.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Ziprasidone.
PrazepamThe metabolism of Prazepam can be decreased when combined with Ziprasidone.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ziprasidone.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Ziprasidone.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Ziprasidone.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Ziprasidone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ziprasidone.
PrilocaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Prilocaine.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Ziprasidone.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Ziprasidone.
PrimidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Primidone.
ProcainamideZiprasidone may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ziprasidone.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Ziprasidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ziprasidone.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Ziprasidone.
ProguanilThe metabolism of Proguanil can be decreased when combined with Ziprasidone.
PromazinePromazine may increase the QTc-prolonging activities of Ziprasidone.
PromazineThe metabolism of Promazine can be decreased when combined with Ziprasidone.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ziprasidone.
PromethazineThe metabolism of Promethazine can be decreased when combined with Ziprasidone.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Ziprasidone.
PropafenonePropafenone may increase the QTc-prolonging activities of Ziprasidone.
ProparacaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Proparacaine.
PropofolThe metabolism of Propofol can be decreased when combined with Ziprasidone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ziprasidone.
PropoxycaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Propoxycaine.
PropranololThe metabolism of Propranolol can be decreased when combined with Ziprasidone.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ziprasidone.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Ziprasidone.
PSD502The risk or severity of adverse effects can be increased when Ziprasidone is combined with PSD502.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Ziprasidone.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Ziprasidone.
QuazepamThe metabolism of Quazepam can be decreased when combined with Ziprasidone.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ziprasidone.
QuetiapineZiprasidone may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Ziprasidone.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Ziprasidone.
QuinidineZiprasidone may increase the QTc-prolonging activities of Quinidine.
QuinineZiprasidone may increase the QTc-prolonging activities of Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Ziprasidone.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Ziprasidone.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Ziprasidone.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ziprasidone.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Ziprasidone.
RanolazineThe metabolism of Ziprasidone can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ziprasidone.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Ziprasidone.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Ziprasidone.
RemifentanilThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Remifentanil.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Ziprasidone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ziprasidone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Ziprasidone.
repinotanThe metabolism of repinotan can be decreased when combined with Ziprasidone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ziprasidone.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Ziprasidone.
RifabutinThe metabolism of Ziprasidone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Ziprasidone can be increased when combined with Rifampicin.
RifapentineThe metabolism of Ziprasidone can be increased when combined with Rifapentine.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Ziprasidone.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Ziprasidone.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Ziprasidone.
RiociguatThe metabolism of Riociguat can be decreased when combined with Ziprasidone.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Ziprasidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ziprasidone.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Ziprasidone.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Ziprasidone.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ziprasidone.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Ziprasidone.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Ziprasidone.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Ziprasidone.
RomifidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Romifidine.
RopiniroleZiprasidone may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Ziprasidone can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Ziprasidone.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ziprasidone.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ziprasidone.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Ziprasidone.
RotigotineZiprasidone may increase the sedative activities of Rotigotine.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Ziprasidone.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ziprasidone.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Ziprasidone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ziprasidone is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Ziprasidone.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Ziprasidone.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Ziprasidone.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Ziprasidone.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Ziprasidone.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Ziprasidone.
ScopolamineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ziprasidone.
SelegilineThe metabolism of Selegiline can be decreased when combined with Ziprasidone.
SelexipagThe metabolism of Selexipag can be decreased when combined with Ziprasidone.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Ziprasidone.
SertindoleThe metabolism of Sertindole can be decreased when combined with Ziprasidone.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Ziprasidone.
SertralineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Sertraline.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Ziprasidone.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ziprasidone.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Ziprasidone.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Ziprasidone.
SilodosinThe metabolism of Silodosin can be decreased when combined with Ziprasidone.
SiltuximabThe serum concentration of Ziprasidone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ziprasidone can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Ziprasidone.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Ziprasidone.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ziprasidone.
Sodium oxybateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Sodium oxybate.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Ziprasidone.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Ziprasidone.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Ziprasidone.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Ziprasidone.
SorafenibSorafenib may increase the QTc-prolonging activities of Ziprasidone.
SotalolZiprasidone may increase the QTc-prolonging activities of Sotalol.
SparteineThe metabolism of Sparteine can be decreased when combined with Ziprasidone.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Ziprasidone.
St. John's WortThe serum concentration of Ziprasidone can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Stiripentol.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Ziprasidone.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ziprasidone.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Ziprasidone.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Ziprasidone.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Ziprasidone.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Ziprasidone.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Ziprasidone.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ziprasidone.
SulpirideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ziprasidone.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Ziprasidone.
SunitinibSunitinib may increase the QTc-prolonging activities of Ziprasidone.
SuvorexantThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Suvorexant.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Ziprasidone.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Ziprasidone.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Ziprasidone.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Ziprasidone.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Ziprasidone.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Ziprasidone.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Ziprasidone.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Ziprasidone.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Ziprasidone.
TasimelteonThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tasimelteon.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Ziprasidone.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Ziprasidone.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ziprasidone.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Ziprasidone.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Ziprasidone.
TelavancinTelavancin may increase the QTc-prolonging activities of Ziprasidone.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Ziprasidone.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Ziprasidone.
TemazepamThe metabolism of Temazepam can be decreased when combined with Ziprasidone.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ziprasidone.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Ziprasidone.
TeniposideThe metabolism of Teniposide can be decreased when combined with Ziprasidone.
TenofovirThe metabolism of Ziprasidone can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Ziprasidone.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Ziprasidone.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Ziprasidone.
TeriflunomideThe serum concentration of Ziprasidone can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Ziprasidone.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Ziprasidone.
TetrabenazineZiprasidone may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetracaine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Ziprasidone.
TetrodotoxinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetrodotoxin.
ThalidomideZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ziprasidone.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ziprasidone.
ThiamylalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Ziprasidone.
ThioridazineThioridazine may increase the QTc-prolonging activities of Ziprasidone.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Ziprasidone.
ThiothixeneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiothixene.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Ziprasidone.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ziprasidone.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Ziprasidone.
TiclopidineThe metabolism of Ziprasidone can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tiletamine.
TimololThe metabolism of Timolol can be decreased when combined with Ziprasidone.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Ziprasidone.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Ziprasidone.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Ziprasidone.
TizanidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tizanidine.
TocilizumabThe serum concentration of Ziprasidone can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Ziprasidone.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ziprasidone.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ziprasidone.
TolcaponeThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tolcapone.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Ziprasidone.
TolterodineTolterodine may increase the QTc-prolonging activities of Ziprasidone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ziprasidone.
TopiramateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Topiramate.
ToremifeneZiprasidone may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Ziprasidone.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ziprasidone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ziprasidone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ziprasidone.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Ziprasidone.
TrazodoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Ziprasidone.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Ziprasidone.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Ziprasidone.
TriazolamThe metabolism of Triazolam can be decreased when combined with Ziprasidone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ziprasidone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Ziprasidone.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Ziprasidone.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Ziprasidone.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ziprasidone.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Ziprasidone.
TriprolidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Ziprasidone.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Ziprasidone.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Ziprasidone.
UdenafilThe metabolism of Udenafil can be decreased when combined with Ziprasidone.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ziprasidone.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Ziprasidone.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Ziprasidone.
Valproic AcidThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Valproic Acid.
VandetanibZiprasidone may increase the QTc-prolonging activities of Vandetanib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Ziprasidone.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Ziprasidone.
VardenafilVardenafil may increase the QTc-prolonging activities of Ziprasidone.
VemurafenibZiprasidone may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ziprasidone.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Ziprasidone.
VerapamilThe metabolism of Verapamil can be decreased when combined with Ziprasidone.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Ziprasidone.
VigabatrinThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Vigabatrin.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Ziprasidone.
VilanterolVilanterol may increase the QTc-prolonging activities of Ziprasidone.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Ziprasidone.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ziprasidone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ziprasidone.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Ziprasidone.
VincristineThe metabolism of Vincristine can be decreased when combined with Ziprasidone.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Ziprasidone.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Ziprasidone.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Ziprasidone.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Ziprasidone.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Ziprasidone.
VorinostatVorinostat may increase the QTc-prolonging activities of Ziprasidone.
VortioxetineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be decreased when combined with Ziprasidone.
XylazineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Xylazine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Ziprasidone.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Ziprasidone.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Ziprasidone.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Ziprasidone.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ziprasidone.
ZiconotideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ziconotide.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Ziprasidone.
ZileutonThe metabolism of Zileuton can be decreased when combined with Ziprasidone.
ZimelidineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Zimelidine.
ZolazepamThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Ziprasidone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ziprasidone.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Ziprasidone.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Ziprasidone.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ziprasidone.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Ziprasidone.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ziprasidone.
ZotepineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Zotepine.
ZuclopenthixolZiprasidone may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  2. Kopecek M, Bares M, Mohr P: Ziprasidone-induced galactorrhea: a case report. Neuro Endocrinol Lett. 2005 Feb;26(1):69-70. [PubMed:15726024 ]
  3. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  6. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Mansbach RS, Carver J, Zorn SH: Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):535-42. [PubMed:11509214 ]
  2. Ichikawa J, Li Z, Dai J, Meltzer HY: Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002 Nov 29;956(2):349-57. [PubMed:12445705 ]
  3. Lu BY, Lundgren R, Escalona PR, Roberts BB: A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics. J Clin Psychiatry. 2002 Dec;63(12):1185-6. [PubMed:12530423 ]
  4. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G: A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004 May;161(5):818-25. [PubMed:15121646 ]
  5. Kast RE, Focosi D, Petrini M, Altschuler EL: Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. Bone Marrow Transplant. 2007 Jun;39(12):811-2. Epub 2007 Apr 23. [PubMed:17450180 ]
  6. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  7. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH: Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology. 1999 Nov;21(5):622-31. [PubMed:10516958 ]
  2. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH: 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000 Aug 1;48(3):229-37. [PubMed:10924666 ]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  4. Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, Fricke JR, Titus CK: The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol. 2002 Apr;22(2):206-10. [PubMed:11910268 ]
  5. Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, Millan MJ: Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):188-99. Epub 2003 Aug 16. [PubMed:12923612 ]
  6. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  7. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001 Aug 17;425(3):197-201. [PubMed:11513838 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  2. Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, Fricke JR, Titus CK: The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol. 2002 Apr;22(2):206-10. [PubMed:11910268 ]
  3. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537 ]
  4. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  5. Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH: Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology. 1999 Nov;21(5):622-31. [PubMed:10516958 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  2. Sanchez C, Arnt J: In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics. Behav Pharmacol. 2000 Jun;11(3-4):291-8. [PubMed:11103883 ]
  3. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537 ]
  4. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  5. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25. [PubMed:17242925 ]
  2. Meltzer HY: The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999 Aug;21(2 Suppl):106S-115S. [PubMed:10432496 ]
  3. Meltzer HY: Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 1995;3(2):64-75. [PubMed:7583621 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Arnt J: Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol. 1995 Sep 5;283(1-3):55-62. [PubMed:7498321 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E: Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J Clin Psychopharmacol. 2010 Feb;30(1):68-71. doi: 10.1097/JCP.0b013e3181c8273d. [PubMed:20075651 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D: Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000;49 Suppl 1:35S-42S. [PubMed:10771452 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Nakamura H, Nakasa H, Ishii I, Ariyoshi N, Igarashi T, Ohmori S, Kitada M: Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. Drug Metab Dispos. 2002 May;30(5):534-40. [PubMed:11950784 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 02:26